Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 136

Similar articles for PubMed (Select 18580862)

1.

Beyond the classic angiotensin-receptor-blocker profile.

Kurtz TW.

Nat Clin Pract Cardiovasc Med. 2008 Jul;5 Suppl 1:S19-26. doi: 10.1038/ncpcardio0805. Review.

PMID:
18580862
2.

Antiproliferative and apoptotic effects of telmisartan in human colon cancer cells.

Lee LD, Mafura B, Lauscher JC, Seeliger H, Kreis ME, Gröne J.

Oncol Lett. 2014 Dec;8(6):2681-2686. Epub 2014 Oct 9.

3.

Telmisartan attenuates cognitive impairment caused by chronic stress in rats.

Wincewicz D, Braszko JJ.

Pharmacol Rep. 2014 Jun;66(3):436-41. doi: 10.1016/j.pharep.2013.11.002. Epub 2014 Apr 2.

PMID:
24905520
4.

Thiazolidinedione-independent activation of peroxisome proliferator-activated receptor γ is a potential target for diabetic macrovascular complications.

Matsumura T, Taketa K, Shimoda S, Araki E.

J Diabetes Investig. 2012 Feb 20;3(1):11-23. doi: 10.1111/j.2040-1124.2011.00182.x. Review.

5.

The possible constitutive activity of wild-type angiotensin II type 1 receptor.

Miura S, Saku K.

Hypertens Res. 2014 Jul;37(7):614-5. doi: 10.1038/hr.2014.61. Epub 2014 Mar 13. No abstract available.

PMID:
24621462
6.

Telmisartan exerts anti-tumor effects by activating peroxisome proliferator-activated receptor-γ in human lung adenocarcinoma A549 cells.

Li J, Chen L, Yu P, Liu B, Zhu J, Yang Y.

Molecules. 2014 Mar 5;19(3):2862-76. doi: 10.3390/molecules19032862.

7.

Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses.

Kakuta H, Kurosaki E, Niimi T, Gato K, Kawasaki Y, Suwa A, Honbou K, Yamaguchi T, Okumura H, Sanagi M, Tomura Y, Orita M, Yonemoto T, Masuzaki H.

J Pharmacol Exp Ther. 2014 Apr;349(1):10-20. doi: 10.1124/jpet.113.211722. Epub 2014 Jan 14.

8.

Telmisartan reduced abdominal circumference and body weight with decreasing triglyceride level in patients with type 2 diabetes and metabolic syndrome.

Kakuma T, Gotoh K, Masaki T, Itateyama E, Abe N, Yoshimatsu H.

Obes Res Clin Pract. 2010 Apr-Jun;4(2):e83-e162. doi: 10.1016/j.orcp.2009.12.003.

PMID:
24345653
9.

Telmisartan ameliorates glutamate-induced neurotoxicity: roles of AT(1) receptor blockade and PPARγ activation.

Wang J, Pang T, Hafko R, Benicky J, Sanchez-Lemus E, Saavedra JM.

Neuropharmacology. 2014 Apr;79:249-61. doi: 10.1016/j.neuropharm.2013.11.022. Epub 2013 Dec 4.

10.

Telmisartan prevents angiotensin II-induced endothelial dysfunction in rabbit aorta via activating HGF/Met system and PPARγ pathway.

Hu ZP, Fang XL, Qian HY, Fang N, Wang BN, Wang Y.

Fundam Clin Pharmacol. 2014 Oct;28(5):501-11. doi: 10.1111/fcp.12057. Epub 2013 Nov 29.

PMID:
24188213
11.

Characterization of telmisartan-derived PPARγ agonists: importance of moiety shift from position 6 to 5 on potency, efficacy and cofactor recruitment.

Herbst L, Goebel M, Bandholtz S, Gust R, Kintscher U.

ChemMedChem. 2012 Nov;7(11):1935-42. doi: 10.1002/cmdc.201200337.

PMID:
24155042
12.

Structure-based identification of novel PPAR gamma ligands.

da Silva FM, dos Santos JC, Campos JL, Mafud AC, Polikarpov I, Figueira AC, Nascimento AS.

Bioorg Med Chem Lett. 2013 Nov 1;23(21):5795-802. doi: 10.1016/j.bmcl.2013.09.010. Epub 2013 Sep 8.

PMID:
24075729
13.

Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.

Casimiro-Garcia A, Heemstra RJ, Bigge CF, Chen J, Ciske FA, Davis JA, Ellis T, Esmaeil N, Flynn D, Han S, Jalaie M, Ohren JF, Powell NA.

Bioorg Med Chem Lett. 2013 Feb 1;23(3):767-72. doi: 10.1016/j.bmcl.2012.11.088. Epub 2012 Dec 1.

PMID:
23265881
14.

Telmisartan modulates mitochondrial function in vascular smooth muscle cells.

Takeuchi K, Yamamoto K, Ohishi M, Takeshita H, Hongyo K, Kawai T, Takeda M, Kamide K, Kurtz TW, Rakugi H.

Hypertens Res. 2013 May;36(5):433-9. doi: 10.1038/hr.2012.199. Epub 2012 Dec 20.

PMID:
23254392
15.

Does the PPAR-γ-activating property of telmisartan provide a benefit in clinical practice?

Fujimura A, Ushijima K, Ando H.

Hypertens Res. 2013 Feb;36(2):183. doi: 10.1038/hr.2012.189. Epub 2012 Nov 29. No abstract available.

PMID:
23190691
16.

Telmisartan ameliorates insulin sensitivity by activating the AMPK/SIRT1 pathway in skeletal muscle of obese db/db mice.

Shiota A, Shimabukuro M, Fukuda D, Soeki T, Sato H, Uematsu E, Hirata Y, Kurobe H, Maeda N, Sakaue H, Masuzaki H, Shimomura I, Sata M.

Cardiovasc Diabetol. 2012 Nov 8;11:139. doi: 10.1186/1475-2840-11-139.

17.

Brain penetration of telmisartan, a unique centrally acting angiotensin II type 1 receptor blocker, studied by PET in conscious rhesus macaques.

Noda A, Fushiki H, Murakami Y, Sasaki H, Miyoshi S, Kakuta H, Nishimura S.

Nucl Med Biol. 2012 Nov;39(8):1232-5. doi: 10.1016/j.nucmedbio.2012.06.012. Epub 2012 Aug 11.

PMID:
22890047
18.

Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies.

Verdecchia P, Dagenais G, Healey J, Gao P, Dans AL, Chazova I, Binbrek AS, Iacobellis G, Ferreira R, Holwerda N, Karatzas N, Keltai M, Mancia G, Sleight P, Teo K, Yusuf S; Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint TrialTelmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease Investigators.

J Hypertens. 2012 May;30(5):1004-14. doi: 10.1097/HJH.0b013e3283522a51.

PMID:
22495138
19.

Prediction and prevention of atrial fibrillation in patients with high blood pressure or history of hypertension.

Kjeldsen SE, Okin PM.

J Hypertens. 2012 May;30(5):887-9. doi: 10.1097/HJH.0b013e328352c507. No abstract available.

PMID:
22495133
20.

Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice.

Min LJ, Mogi M, Shudou M, Jing F, Tsukuda K, Ohshima K, Iwanami J, Horiuchi M.

Hypertension. 2012 May;59(5):1079-88. doi: 10.1161/HYPERTENSIONAHA.112.192401. Epub 2012 Mar 26.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk